Graham Faces Tough Agenda In Science Post

WASHINGTON-William Graham, confirmed Oct. 1 as presidential science adviser and director of the White House Office of Science and Technology Policy, faces a scientific community skeptical of his ability to affect science policy but hopeful he can represent their interests before the administration. He assumed office in the White House the following day shortly after 3 p.m. The voice vote in the Senate ended a nine-month search for a successor to George Keyworth II, who left the administration J

| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

WASHINGTON-William Graham, confirmed Oct. 1 as presidential science adviser and director of the White House Office of Science and Technology Policy, faces a scientific community skeptical of his ability to affect science policy but hopeful he can represent their interests before the administration.

He assumed office in the White House the following day shortly after 3 p.m. The voice vote in the Senate ended a nine-month search for a successor to George Keyworth II, who left the administration Jan. 1 to form a consulting company. John McTague and Richard Johnson served successively as acting directors in the interim.

Graham, 49, is an electrical engineer from southern California who was named deputy administrator of the National Aeronautics and Space Administration six weeks before the Challenger accident in January. He served as acting administrator until James Fletcher was appointed last spring.

"He took steps to restore stability to this agency in very ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies